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Abstract: Dystonia is a movement disorder of uncertain pathogenesis that is characterized by 
involuntary and inappropriate muscle contractions which cause sustained abnormal postures 
and movements of multiple or single (focal) body regions. The most common focal dystonias 
are cervical dystonia (CD) and blepharospasm (BSP). The first-line recommended treatment for 
CD and BSP is injection with botulinum toxin (BoNT), of which two serotypes are available: 
BoNT type A (BoNT/A) and BoNT type B (BoNT/B). Conventional BoNT formulations include 
inactive complexing proteins, which may increase the risk for antigenicity, possibly leading to 
treatment failure. IncobotulinumtoxinA (Xeomin®; Merz Pharmaceuticals GmbH, Frankfurt, 
Germany) is a BoNT/A agent that has been recently Food and Drug Administration-approved for 
the treatment of adults with CD and adults with BSP previously treated with onabotulinumtoxinA 
(Botox®; Allergen, Inc, Irvine, CA) – a conventional BoNT/A. IncobotulinumtoxinA is the only 
BoNT product that is free of complexing proteins. The necessity of complexing proteins for 
the effectiveness of botulinum toxin treatment has been challenged by preclinical and clinical 
studies with incobotulinumtoxinA. These studies have also suggested that incobotulinumtoxinA 
is associated with a lower risk for stimulating antibody formation than onabotulinumtoxinA. 
In phase 3 noninferiority trials, incobotulinumtoxinA demonstrated significant improvements 
in CD and BSP symptoms in both primary and secondary measures, compared with baseline, 
and met criteria for noninferiority versus onabotulinumtoxinA. In placebo-controlled trials, 
incobotulinumtoxinA also significantly improved the symptoms of CD and BSP, with robust 
outcomes in both primary and secondary measures. The use of incobotulinumtoxinA has been 
well tolerated in all trials, with an adverse event profile similar to that of onabotulinumtoxinA. 
Based on these data, incobotulinumtoxinA is a safe and effective BoNT/A for the treatment 
of CD and BSP, and may pose a lower risk for immunogenicity leading to treatment failure 
compared with other available BoNT agents. This paper reviews the treatment of focal dystonias 
with BoNTs, in particular, incobotulinumtoxinA. Controlled trials from the existing incobotu-
linumtoxinA literature are summarized.
Keywords: blepharospasm, botulinum toxin, cervical dystonia, complexing proteins, dystonia, 
incobotulinumtoxinA (Xeomin®)
Introduction
Dystonia is a movement disorder characterized by sustained, involuntary muscle con-
tractions that lead to repetitive twisting movements and abnormal postures in affected 
areas, including the head, neck, face, trunk, or arms and legs.1,2 These symptoms result 
from concomitant contraction of agonist and antagonist muscles, with overflow into 
adjacent muscles.1 The pathophysiology of dystonia is still unclear, but it is believed 
to involve a deficiency of cortical motor inhibition, possibly stemming from a motor 
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network dysfunction associated with abnormalities in the 
  sensorimotor cortex, basal ganglia, and cerebellum.1,3–5 
  Dystonia is variously classified according to whether it is pri-
mary (idiopathic) or secondary to other neurologic conditions, 
injuries, abnormalities, or drug effects; childhood- or adult-
onset; and the body area(s) affected.1 When described based 
on body distribution, classifications of dystonia include: (1) 
focal, in which one region, such as craniofacial, neck, limb, 
or axial (shoulders, trunk), is involved, (2)   segmental, which 
includes $2 adjacent regions, (3) multifocal, in which $2 
nonadjacent regions are involved, (4) generalized, which may 
include one or both legs, the trunk, and/or other regions, and 
(5) hemidystonia, in which the ipsilateral arms and legs are 
affected.1,6 Focal dystonias occur most frequently in adults, 
whereas generalized dystonias often begin in childhood.2 
Primary, adult-onset, focal dystonia is by far the most com-
mon type of dystonia.1,7–9
The two most common types of focal dystonias, in order 
of prevalence, are cervical dystonia (CD; also known as 
spasmodic torticollis) and blepharospasm (BSP),7,10 although 
BSP has been reported to be more common than CD in 
specific populations.11–13 The estimated prevalence of these 
disorders has been reported to be between six and nine per 
100,000 for CD and about three per 100,000 for BSP.7,10,14 
Both CD and BSP are associated with multiple adverse 
effects on quality of life, including social and occupational 
dysfunction and disability, embarrassment, anxiety, and 
depression.15–19
CD is characterized by involuntary contractions of cervical 
muscles that cause abnormal head movements and postures, 
and may feature jerking or twisting movements, transient 
spasms, shoulder elevation, stiffness/tightness, and an irregu-
lar jerky head tremor.15,20 Individuals with BSP, on the other 
hand, exhibit involuntary, repetitive, spasmodic, and sustained 
eyelid closure.21,22 A hallmark of both BSP and CD, as well as 
other forms of dystonia, is the presence of a sensory trick, or 
“geste antagoniste,” that may assist a patient in maintaining 
a normal posture.23 Mean age at onset is about 41 years for 
persons with CD and 56 years for those with BSP.24 Despite 
these differences in clinical features, CD and BSP may share 
etiologic and pathophysiologic mechanisms.25 In patients with 
CD, BSP occurs concomitantly in approximately 10% of those 
affected,20,26 and about 30% of patients with BSP experience 
spread of dystonic symptoms to the neck.27 Both CD and BSP 
appear to be associated with a bilateral reduction in striatal 
postsynaptic dopamine D2 receptor binding, as indicated 
by functional imaging studies,28–30 although recent findings 
suggest that the defect in focal dystonia may be in D3, rather 
than D2, receptor expression.31 In addition, both CD and BSP 
have been associated with enhancement of the blink reflex, 
which suggests hyperexcitability of brainstem pathways,32–34 
impaired recognition of facial expression of disgust, which 
involves basal ganglia activation,35 and bilateral impaired 
sensory spatial discrimination, which suggests abnormal 
sensory processing within the somatosensory cortex.36 
A brain voxel-based morphometry study also revealed similar 
alterations in gray matter structures related to sensorimotor 
processing in patients with BSP and CD.37
The aim of this review is to familiarize the clinician with 
the differing biological and physical properties of botulinum 
toxins (BoNTs) used for treatment of focal dystonias and 
to summarize the clinical profile of incobotulinumtoxinA 
(Xeomin®; Merz Pharmaceuticals GmbH, Frankfurt, 
  Germany), the most recently Food and Drug Administration 
(FDA)-approved BoNT.
Methods
The clinical data for incobotulinumtoxinA summarized in this 
review were obtained by performing a PubMed search using 
the terms “Xeomin,” “NT201,” “NT 201,” and “incobotuli-
numtoxinA.” Two phase 1 trials in healthy volunteers were 
identified in the search and were included in the review. All 
clinical trials in focal dystonia (CD or BSP) identified via 
this search were also included; additionally, pooled analyses 
and subanalyses generated from these trials and presented 
at society conferences were included. All the clinical trials 
in focal dystonia were well-controlled, double-blind trials 
with the exception of an open-label immunogenicity trial in 
CD that reported an objective outcome measure: presence 
of neutralizing antibodies.
BoNT treatment of focal  
dystonia: overview
BoNT is the first-line recommended treatment for most types 
of focal dystonia, including both CD and BSP.38,39 BoNT 
acts primarily by binding with high specificity and affin-
ity to presynaptic cholinergic axon terminals and blocking 
the release of acetylcholine into the neuromuscular junc-
tion, thereby causing temporary denervation and muscle 
  weakness for periods typically lasting 3–4 months.40,41 A total 
of seven antigenically distinct serotypes (types A–G) of 
naturally occurring toxin have been isolated from unique 
strains of Clostridium botulinum. These serotypes vary by 
their mechanism of blocking fusion of the acetylcholine-
containing synaptic vesicle with the cell membrane, thereby 
preventing neurotransmitter release into the neuromuscular 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
14
Jimenez-ShahedNeuropsychiatric Disease and Treatment 2012:8
junction and achieving denervation (Figure 1).40,41 BoNT 
type A (BoNT/A) cleaves the target protein synaptosomal-
associated protein 25 and BoNT type B (BoNT/B) cleaves 
synaptobrevin-2 (Figure 1); these serotypes are used in 
clinical practice.40,41
The most commonly used BoNT treatments include three 
BoNT/A products and one BoNT/B product, each of which 
has a unique generic name designated by the FDA for use 
in the United States (Table 1).42,43 All of these agents have 
demonstrated efficacy in clinical trials, but they have vary-
ing pharmacologic properties including potency, dosing, 
constituents and excipients, storage requirements, and toler-
ability profiles (Table 1).38,39,41,44–46 However, only a modest 
number of randomized, controlled clinical trials comparing 
BoNT agents in patients with focal dystonia have been 
reported in the literature.44,45,47–51
Currently-marketed BoNT agents may vary with respect 
to their risk for stimulating antibody formation, lead-
ing to immunoresistance and the potential for treatment 
failure.41,52,53 In patients being treated for CD, de novo treat-
ment with BoNT/B has been associated with a high rate of 
immunoresistance, contributing to treatment failure in up to 
44% of individuals.54 The rate of immunoresistance in type A 
agents appears to range from ,1% to 5%.2,53,55 Possible risk 
factors for immunoresistance include higher doses, the total 
amount of clostridial protein administered, and increased 
duration and frequency of treatment.52,53 Clinical data also 
suggest that patients may vary in their immune reactivity to 
similar doses of BoNT.53 The issue of immunoresistance is 
of particular importance in patients with dystonia, because 
limited options are available for the management of BoNT/A 
failure. For example, a study of ten patients with CD who 
had experienced complete therapeutic failure with BoNT/A 
found that alternative BoNT/B treatment induced a stable 
therapeutic response in three of the participants, but only 
a temporary response followed by treatment failure in the 
remainder of the individuals.56
The presence of nontoxic hemagglutinizing and non-
hemagglutinizing complexing proteins in several of the 
available BoNT agents (Table 1) may also lead to immunore-
sistance.53,57 The neurotoxin present in all serotypes of BoNT 
(types A–G) is noncovalently associated with complexing 
S
S
L L
Zn
BTX–B, D, F, G, TeTx
BTX–A, E, C1 BTX–C
VAMP/
synaptobrevin
SNAP-25 Syntaxin Plasma membrane
Steps:1 23 4
Synaptic
vesicle H
BTX
Figure 1 The mechanism of action of botulinum toxins involves a four-step process: 
(1) activation by proteolytic cleavage of the polypeptide chain into a 100 kDa heavy 
chain (H) and a 50 kDa light chain (L), linked by a disulfide bond (S–S), and binding of 
the H to the presynaptic membrane of the motor axon terminal, (2) internalization 
of the toxin complex by energy-dependent endocytosis, (3) release of the L into the 
cytoplasm, and (4) cleaving by the L at various sites (vertical arrows), depending on 
the serotype, thus preventing fusion of the acetylcholine-containing synaptic vesicle 
with the cell membrane at the neuromuscular junction.40 
Reprinted with permission.40
Abbreviations: BTX, botulinum toxin; SNAP-25, synaptosomal-associated protein 
25; vAMP, vesicle-associated membrane protein; Zn, zinc. 
Table 1 Marketed brands of botulinum toxins42,43
Generic name OnabotulinumtoxinA RimabotulinumtoxinB AbobotulinumtoxinA IncobotulinumtoxinA
Brandname Botox Myobloc/Neurobloca Dysport Xeomin
Manufacturer Allergan, inc. 
(United States)
Solstice Neurosciences  
(United States)
ipsen (France) Merz Pharmaceuticals 
GmbH (Germany)
Serotype A B A A
Specific activity, U/ng 20 75–125 40 167
Packaging, units/ vial 100 2500, 5000, or 10000 500 100
Constituents and excipients Hemagglutinin and 
nonhemagglutin proteins, 
human albumin, saccharose, 
sodium chloride
Hemagglutinin and nonhemagglutin 
proteins,human albumin solution 
0.05%, sodium chloride, sodium 
succinate
Hemagglutinin and 
nonhemagglutin proteins, 
human albumin solution 
20%, lactose
Human albumin, 
saccharose
pH 7.4 5.6 7.4 7.4
Molecular weight, kDa 900 700 500–900 150
Preparation vacuum-dried Solution (5000 U/mL) Lyophilized Lyophilized
Storage of packaged product 2°C to 8°C 2°C to 8°C 2°C to 8°C Room temperature
Storage once reconstituted 2°C to 8°C for 
24 hours
Does not require reconstitution 2°C to 8°C for 
4 hours
2°C to 8°C for  
24 hours
Notes: aMyobloc is the brand name in Canada, the United States, and Korea; Neurobloc is the brand name in the European Union, Norway, and iceland.
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proteins to form toxin complexes, which are encoded in 
two gene clusters57 and are present in the natural state. The 
first cluster encodes the actual neurotoxin and a nontoxic, 
nonhemagglutinin protein, and the second cluster encodes 
three hemagglutinin proteins (HA1, HA2, and HA3).58,59 Two 
different complexes are produced by C. botulinum (serotypes 
A–D and G): a complex containing the toxin and the nontoxic, 
nonhemagglutinin protein (300 kDa), and a larger complex 
containing the toxin and HA1–3 (500–600 kDa). Serotype 
A also forms a third complex with an even higher molecular 
weight. This complex contains the toxin and nontoxic, nonhe-
magglutinin protein in addition to varying numbers of other 
hemagglutinin proteins (880–1000 kDa in total).57 Based on 
experimental studies, the natural functions of the complexing 
proteins appear to include protecting the neurotoxin from low 
pH and proteases, stabilizing the neurotoxin’s biologic activ-
ity, and facilitating adherence of the neurotoxin to muscle 
tissues,57,60–62   suggesting a role in preventing degradation 
of the toxin within the gastrointestinal tract and increas-
ing the likelihood of absorption – hence, a biologic effect. 
  Hypothetically, by increasing the size (molecular weight) of 
the toxin complex, complexing proteins may also limit dif-
fusion of the neurotoxin out of the target tissue, potentially 
lowering the risk for such diffusion-related adverse events 
(AEs) as dysphagia in patients with CD.62,63 Experimental 
studies suggest, however, that BoNT complexing proteins 
are not essential for the clinical activity of the neurotoxin 
in humans, because at increasing pH levels, the complexes 
quickly dissociate at an increasing rate.64 At physiologic pH 
in humans, this process occurs in ,1 minute,65 whereas the 
clinical effect is known to become augmented over days. 
Experimental and clinical studies have also shown that 
complexing proteins do not appear to modify the diffusion 
of BoNT from target tissues.64–68
In addition, assay studies have found that complexing 
proteins have significantly greater immunogenicity than does 
the purified neurotoxin alone, with antibody formation up 
to 60 times greater in reaction to the BoNT complex and 
up to 35 times greater in reaction to the complexing hemag-
glutinins, compared with the neurotoxin alone.69–71 Although 
the precise relationship between antibody formation and 
treatment failure is unclear, almost half of all secondary 
nonresponders to BoNT therapy for focal dystonia screen 
positive for antibody formation.72 It has been speculated 
that the immune activity generated by the presence of 
complexing proteins can induce a greater likelihood of an 
antigenic response against the neurotoxin itself – that is, a 
neutralizing antibody.
Review of incobotulinumtoxinA
History of development
IncobotulinumtoxinA (Xeomin) is a highly purified BoNT/A 
agent and the only BoNT product that is free of any   complexing 
clostridial proteins (Table 1).65 IncobotulinumtoxinA is 
  FDA-approved for the treatment of adults with CD in both 
BoNT-naïve individuals and previously-treated patients, and 
for the treatment of BSP in adults previously treated with 
onabotulinumtoxinA (Botox®; Allergen, Inc, Irvine, CA).73 
Prior to the development of incobotulinumtoxinA, the manu-
facturing process of BoNT agents was hampered by a mas-
sive degradation of about 90% of the neurotoxin, with this 
proportion inactive and behaving as a toxoid.65 A high level of 
inactive clostridial protein in a BoNT formulation is clinically 
important, because it increases the total amount of clostridial 
protein that must be administered to achieve a therapeutic 
effect, which, as noted, may increase the risk for an immune 
reaction.65,74 In addition, both the diffusion of BoNT and the 
incidence of BoNT-related AEs have been observed to be 
dose-dependent.75–77
In view of these factors, a manufacturing process for 
incobotulinumtoxinA was devised that involves a series of 
steps to separate and purify the neurotoxin complex, eliminate 
the complexing proteins, minimize degradation, and prevent 
loss of biologic activity during dilution, formulation, and 
lyophilization.65 As a result, incobotulinumtoxinA contains 
only the pure 150 kDa neurotoxin and contains 0.6 ng of 
protein per every 100 U vial.65 By contrast, there is about 
55 ng of protein in a vial of rimabotulinumtoxinB (Myobloc®/
Neurobloc®; Solstice Neurosciences, Malvern, PA), 5 ng in a 
vial of onabotulinumtoxinA, and 4.35 ng in a vial of abobotu-
linumtoxinA (Dysport®; Ipsen, Paris, France).65,66 Complexing 
proteins add to the molecular weight of the injected solution 
and may hypothetically enhance the stability of the product 
and limit its diffusion to adjacent tissues. Given that incobotu-
linumtoxinA lacks the complexing proteins of other BoNT 
agents, it was evaluated for these pharmacologic properties, 
as well as for safety, tolerability, and efficacy.
Pharmacologic profile
Stability studies conducted in accordance with the FDA 
guidelines for stability testing of drug products78 revealed   
that incobotulinumtoxinA remained stable and highly potent 
when stored for 4 years at room temperature, thereby demon-
strating that complexing proteins are not necessary for stabili-
zation of a BoNT formulation prior to injection.79 To address 
concerns about the greater risk for toxin spread, a randomized, 
controlled, double-blind, 52-week trial in 32 male volunteers68 
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was conducted to study diffusion into adjacent muscles of 
incobotulinumtoxinA compared with the higher molecular 
weight onabotulinumtoxinA. All subjects were injected with 
one agent in the extensor digitorum brevis (EDB) muscle of 
one foot and the other agent in the EDB of the contralateral 
foot, in equal doses (2, 4, 16, or 32 U). Surface electromyo-
graphy was used to measure whether the amplitude of the 
compound muscle action potential (CMAP) in the adjacent 
muscles had been reduced with either   neurotoxin. The study 
found that all incobotulinumtoxinA and onabotulinumtoxinA 
doses significantly reduced the CMAP M-wave amplitudes 
in the target EDB muscles in a dose-dependent fashion, 
with similar reductions in CMAP M-wave amplitudes in 
muscles adjacent to the EDB   (abductor digiti quinti and 
abductor hallucis).68 In fact, the CMAP M-wave amplitudes 
remained above the predefined threshold of effect, indicating 
that no clinically relevant diffusion had occurred. Hence, the 
absence of complexing proteins in BoNT formulations does 
not appear to increase the risk for diffusion of toxin.
Preclinical animal studies were also conducted to 
evaluate the immunogenicity of incobotulinumtoxinA. In 
a comparison study, female New Zealand white rabbits 
(n = 20 per group) received intracutaneous administration 
of either incobotulinumtoxinA or onabotulinumtoxinA at 
16 lethal dose units per animal (approximately 5.34 lethal 
dose units/kg) for eight administrations at 2- to 8-week 
intervals, with a booster injection of 25 lethal dose units 
per animal at 10 weeks following the eighth injection.80 
Sera from both groups were initially screened for BoNT/A 
antibodies using an enzyme-linked immunosorbent assay, 
and antibody-positive sera were then tested for their ability 
to neutralize the paralytic effects of BoNT/A in a mouse 
hemidiaphragm assay. At week 36 – 3 weeks after the final 
(booster) injection – the enzyme-linked immunosorbent 
assay showed that seven of the 20 rabbits in the onabotuli-
numtoxinA group screened positive for BoNT/A antibodies, 
with four of these rabbits displaying BoNT/A-neutralizing 
activity in the hemidiaphragm assay. In contrast, one rabbit 
in the incobotulinumtoxinA group tested positive by enzyme-
linked immunosorbent assay, but no neutralizing activity 
was detected in the hemidiaphragm assay. Considering the 
high doses and short injection intervals used in this study, 
these results suggest that incobotulinumtoxinA, without 
complexing proteins, poses a lower risk for immunogenic-
ity leading to treatment failure than does the conventionally   
prepared BoNT/A agent that contains such proteins.80
Other preclinical animal studies have demonstrated a 
similar pharmacologic profile of incobotulinumtoxinA and 
onabotulinumtoxinA with respect to pharmacodynamic 
action, effects on cardiovascular function and   toxicity 
  following single or repeated dose administrations.80 
In addition, two phase 1   clinical studies in healthy volunteers 
showed that   treatment with either incobotulinumtoxinA or 
  onabotulinumtoxinA was associated with similar times to onset 
and duration of effect, as measured by surface electromyogra-
phy of the injected EDB muscle.68,81 The degree of reduction in 
CMAP amplitudes at 3 months following the injection is iden-
tical between the two toxin products.81 Taken together, these 
studies indicate that the clinical effects of a BoNT/A product 
free of complexing proteins should be no different from those 
of a conventionally prepared BoNT/A formulation.
Efficacy in patients with CD
The efficacy, safety, and tolerability of incobotulinumtoxinA 
have been evaluated in multiple clinical trials in patients 
with CD. The largest trial to date was a randomized, active-
controlled, double-blind, phase 3 study designed to determine 
whether incobotulinumtoxinA was noninferior in efficacy to 
onabotulinumtoxinA in patients with CD.51 The study, which 
was conducted at 51 centers in eleven European countries,51 
enrolled 463 patients with a documented stable therapeutic 
response to onabotulinumtoxinA over the prior two injec-
tion sessions, with the last   onabotulinumtoxinA injection 
administered at least 10 weeks prior to randomization.51,82 
The patients were randomized to either   incobotulinumtoxinA 
or onabotulinumtoxinA at the same doses they had received 
in the previous two prerandomization sessions with 
  onabotulinumtoxinA. The dosage ranged from 70 U to 300 U, 
with a control visit conducted 4 weeks after injection and 
follow-up visits for up to 16 weeks. The primary efficacy 
variable was the change from baseline in the Toronto Western 
Spasmodic Torticollis Rating Scale (TWSTRS)83 severity 
score (0–35) at 28 ± 7 days postinjection. At baseline, patients 
in both the incobotulinumtoxinA group (n = 209) and the 
onabotulinumtoxinA group (n = 205) had a median TWSTRS 
severity score of 18, indicating moderate severity.
In both groups, these scores improved to a median of 
eleven points at day 28, with an average change of −6.6 points 
in the incobotulinumtoxinA group and −6.4 points in the 
onabotulinumtoxinA group (P , 0.0001, analysis of cova-
riance, both agents; Figure 2). The median dose injected 
was 120 U in the incobotulinumtoxinA group and 122.5 U 
in the onabotulinumtoxinA group. In the noninferiority 
assessment, the least-squares mean difference between the 
groups was −0.33 points (favoring incobotulinumtoxinA) 
and the upper limit of the corresponding 95% confidence 
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interval was lower than the predefined difference of 1.3 
points in all analysis of covariance models, thereby dem-
onstrating the noninferiority of incobotulinumtoxinA to 
  onabotulinumtoxinA for the treatment of CD. In addition, 
no relevant differences in any secondary variables were 
reported between the two groups, including the TWSTRS 
severity score at the final visit, the TWSTRS pain subscore 
at the control and final visits, and the visual analog scale 
pain score at the control and final visits (Table 2). Both 
treatments were also very similar in terms of time to onset 
of effect, time to waning of effect, and total duration of 
effect (Table 2). AEs were reported by similar   percentages 
of patients in the   incobotulinumtoxinA (28.1%) and 
onabotulinumtoxinA (24.1%) groups (Table 3), and serious 
AEs (SAEs) occurred in four   incobotulinumtoxinA-treated 
patients and five onabotulinumtoxinA-treated patients.51 
All SAEs were judged either unrelated or unlikely to 
be related to treatment.51 The results of this study sug-
gest that incobotulinumtoxinA, when administered at 
the same doses as prior successful onabotulinumtoxinA 
treatments, is noninferior in clinical efficacy to onabotu-
linumtoxinA for the treatment of CD and has a similar 
side effect profile.
Another study investigated the safety and efficacy of 
incobotulinumtoxinA versus placebo in 233 patients with 
CD, including BoNT-naïve patients (39% of the population) 
and nonnaïve individuals (previously treated with BoNT/A 
or BoNT/B), at a low (120 U) and high (240 U) dose.84 The 
dosing design of this study was based on the median dose 
used in the noninferiority trial of incobotulinumtoxinA 
and onabotulinumtoxinA (120 U),51 and the typical dose 
used in other trials of BoNT/A agents for the treatment 
of CD (240 U).85 This randomized, placebo-controlled 
trial, conducted at 37 study centers in the United States, 
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Figure 2 Average changes in Toronto western Spasmodic Torticollis Rating Scale 
(TwSTRS) severity score following treatment with either incobotulinumtoxinA or 
onabotulinumtoxinA in adults with cervical dystonia. 
Note: *P , 0.0001 versus baseline (analysis of covariance).51,82
Table 2 Secondary efficacy variables in noninferiority trial of IncobotulinumtoxinA vs OnabotulinumtoxinA51
Variable IncobotulinumtoxinA OnabotulinumtoxinA Treatment 
comparison 
P value
Mean (SD) P value, compared  
with baseline
Mean (SD) P value, compared  
with baseline
TwSTRS severity score  
at final visit
–1.8 (3.4) 
(n = 209)
,0.0001a –1.8 (3.8) 
(n = 205)
,0.0001a 0.74a
TwSTRS pain subscore  
at control visit
–0.4 (0.8) 
(n = 213)
,0.0001b –0.6 (1.0) 
(n = 207)
,0.0001b 0.41b
TwSTRS pain subscore  
at final visit
–0.1 (0.9) 
(n = 210)
0.12b –0.2 (1.0) 
(n = 205)
0.003b 0.09b
vAS pain score  
at control visit
–8.8 (18.5) 
(n = 210)
,0.0001b –11.8 (19.4) 
(n = 206)
,0. 0001b 0.3b
vAS pain score  
at final visit
–1.4 (22.0) 
(n = 207)
0.5b –4.5 (20.2) 
(n = 204)
0.002b 0.06b
Time to event, mean (SD) Relative risk 
P valuec
Onset of effect, days 7.3 (4.3) 
(n = 189)
7.2 (4.1) 
(n = 182)
0.96
waning of effect, weeks 9.9 (3.8) 
(n = 181)
10.0 (3.9) 
(n = 167)
0.88
Duration of effect, days 95.9 (30.0) 
(n = 192)
94.3 (31.4) 
(n = 180)
0.91
Notes: aAnalysis of covariance; bwilcoxon; cCox regression.
Abbreviations: SD, standard deviation; TwSTRS, Toronto western Spasmodic Torticollis Rating Scale; vAS, visual analog scale.
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Subanalyses of the data from this placebo-controlled trial 
were also conducted in the subgroups of BoNT-naïve and 
nonnaïve patients. In the toxin-naïve patients (n = 90), the 
changes from baseline to week four in total TWSTRS score 
with incobotulinumtoxinA 120 U and incobotulinumtoxinA 
240 U were −11.9 ± 11.1 points and −10.0 ± 9.2 points, 
respectively, versus −2.0 ± 6.0 with placebo (P , 0.001 
for both doses).86 Changes in the TWSTRS severity score 
from baseline to week four in the incobotulinumtoxinA 
120-U group and the incobotulinumtoxinA 240-U group 
were −4.1 ± 4.3 points and −5.4 ± 5.5 points, respectively, 
versus −1.9 ± 4.5 points in the placebo group. Compared 
with placebo, incobotulinumtoxinA was well tolerated, 
with dysphagia, muscular weakness, and neck pain the 
most frequently reported AEs with active treatment, which 
is similar to that with other toxins. The subanalysis in the 
patients previously treated with another BoNT product 
(n = 143) showed that the mean changes in total TWSTRS 
score from baseline to week four with incobotulinumtoxinA 
120 U and incobotulinumtoxinA 240 U were −8.5 ± 9.7 
points and −11.4 ± 13.1 points, respectively, compared 
with −2.4 ± 9.1 points with placebo (P , 0.002 for both 
doses).87 The improvements in TWSTRS severity score from 
baseline to week four with   incobotulinumtoxinA 120 U and 
incobotulinumtoxinA 240 U were −3.7 ± 4.4 points and 
−5.6 ± 6.4 points, respectively, versus −1.9 ± 3.7 points with   
placebo. AEs occurred in 55.3% of patients in the inco-
botulinumtoxinA 120-U group, 46.0% in the incobotuli-
numtoxinA 240-U group, and 34.8% in the placebo group. 
The most common AEs were dysphagia, neck pain, and 
injection-site pain, which was similar to those reported in 
the trial of BoNT-naïve patients.86
Taken together, the placebo-controlled study in patients with 
CD and subanalyses of the data showed that incobotulinum-
toxinA generally has similar efficacy and tolerability at doses of   
120 U and 240 U, and across BoNT-naïve and nonnaïve 
patient subgroups.
Long-term safety and tolerability  
in patients with CD
The first long-term safety and tolerability evaluation of 
incobotulinumtoxinA88 was conducted as an extension of 
the above-described efficacy study in 233 patients with 
CD, including both BoNT-naïve patients and those who 
had been previously treated with BoNT (type A or B).84 
Patients who completed the #20-week randomized,   
placebo-controlled study were eligible to enter the exten-
sion phase and were treated with incobotulinumtoxinA 
Table 3 Adverse events following a single injection of either 
incobotulinumtoxinA  or  onabotulinumtoxinA  in  463  patients 
with cervical dystonia51
Adverse event,  
n (%)
IncobotulinumtoxinA 
(n = 231)
OnabotulinumtoxinA 
(n = 232)
All 
Dysphagia 
Skeletal pain 
Back pain 
Muscle weakness 
Headache 
vomiting 
Erythematous rash 
Diarrhea 
Fatigue 
Arthralgia 
Asthenia 
Myalgia 
Mouth dryness 
Dizziness
65 (28.1) 
25 (10.8) 
8 (3.5) 
5 (2.2) 
4 (1.7) 
2 (0.9) 
2 (0.9) 
2 (0.9) 
1 (0.4) 
1 (0.4) 
3 (1.3) 
2 (0.9) 
2 (0.9) 
1 (0.4) 
2 (0.4)
56 (24.1) 
19 (8.2) 
5 (2.2) 
2 (0.9) 
1 (0.4) 
3 (1.3) 
2 (0.9) 
2 (0.9) 
3 (1.3) 
3 (1.3) 
0 (0.0) 
1 (0.4) 
1 (0.4) 
2 (0.9) 
2 (0.9)
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Figure 3 Mean change from baseline at week four in Toronto western Spasmodic 
Torticollis Rating Scale (TwSTRS) total score in 233 botulinum toxin type B-naïve 
and  nonnaïve  patients  with  cervical  dystonia  treated  with  incobotulinumtoxinA 
120 U, incobotulinumtoxinA 240 U, or placebo. 
Note: *P , 0.001 versus placebo.85
found that the changes from baseline to week four in 
total TWSTRS score were −9.9 ± 10.4 points with inco-
botulinumtoxinA 120 U and −10.9 ± 11.7 points with 
incobotulinumtoxinA 240 U, compared with −2.2 ± 7.3 
points with placebo (P , 0.001 versus placebo for both 
incobotulinumtoxinA groups)   (Figure 3). AEs occurred 
in 55.1% of patients in the   incobotulinumtoxinA 120-U 
group, 56.8% in the   incobotulinumtoxinA 240-U group, and 
45.9% in the placebo group. The most frequently reported 
AEs – dysphagia, neck pain, and muscular weakness – were 
similar to those observed in the other incobotulinumtoxinA 
4-week trials.84
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(120 U or 240 U; #5 injections) over 1 year (48-week 
treatment and 20-week follow-up). A total of 217 patients 
entered the extension phase, with 153 of them participat-
ing in the long-term safety analysis. The mean duration of 
time prior to reinjection was 10.0–14.5 weeks. During the 
extension period, 118 of the 153 patients (77.1%) experi-
enced at least one AE (70.7% in the 120-U group; 83.3% 
in the 240-U group). The most frequently reported AEs 
were dysphagia, neck pain, and sinusitis. No SAEs were 
judged to be related to the incobotulinumtoxinA treatment, 
and the total incidence of AEs decreased with each injec-
tion interval, thus indicating no cumulative effect from 
repeated doses.88
immunogenicity in patients with CD
The immunogenicity of incobotulinumtoxinA in persons with 
CD is being evaluated in an ongoing, open-label study of 
100 patients.82 In this study, 50 consecutive de novo patients 
and an additional 50 patients who had been previously treated 
with one of the three BoNT products now available in the 
United States (Table 1) were switched to incobotulinumtoxinA 
treatment at a dose relationship of 1:1 for   onabotulinumtoxinA 
and 1:4 for   abobotulinumtoxinA. Patients previously treated 
with rimabotulinumtoxinB had been switched from either 
onabotulinumtoxinA or   abobotulinumtoxinA because of 
nonresponse related to immunoresistance. Antibody testing 
performed after 1 year and 2 years of continuous treatment 
with incobotulinumtoxinA demonstrated that no patient had 
developed secondary nonresponsiveness or antiBoNT/A 
neutralizing antibodies, including 100 patients who had 
been treated for .1 year and 34 patients who were treated 
continuously for .2 years. However, six patients who had 
experienced secondary nonresponsiveness as a result of 
antibody formation during their prior treatment with onabotu-
linumtoxinA or   abobotulinumtoxinA also failed to achieve 
clinical benefit with incobotulinumtoxinA, underscoring the 
importance of minimizing the risk for immunoresistance from 
treatment onset.82
Efficacy in patients with BSP
A phase 3 randomized, active-controlled, double-
blind, noninferiority study comparing the efficacy of 
  incobotulinumtoxinA with that of onabotulinumtoxinA 
in patients with BSP was conducted at 42 study centers 
in Europe and Israel.89 In this trial, 300 patients with 
BSP who had received at least two prior injections with 
onabotulinumtoxinA that yielded a stable response were 
randomized to either   incobotulinumtoxinA (n = 148) or 
onabotulinumtoxinA (n = 152), with a maximum dose of 
35 U per eye, and followed for 16 weeks with a control 
visit at 3 weeks. The primary efficacy variable was change 
from baseline in the sum score of the   Jankovic Rating Scale 
(JRS) at the control visit (21 ± 1 days postinjection).89 
Each of the treatments resulted in similar reductions in 
JRS scores of −2.90 in the   incobotulinumtoxinA group 
and −2.67 in the   onabotulinumtoxinA group, both of which 
were significant compared with baseline (P , 0.0001, 
  analysis of covariance, for both; Figure 4). The difference 
between the two adjusted group means was −0.23, with 
the upper limit of the 95% confidence interval amount-
ing to 0.22.89 This was below the predefined limit for 
noninferiority (0.8), thus demonstrating that incobotuli-
numtoxinA was noninferior to onabotulinumtoxinA for 
the treatment of patients with BSP. The noninferiority of 
  incobotulinumtoxinA to onabotulinumtoxinA was also 
supported by the results for secondary variables, including 
mean change from baseline at the control visit in scores on 
the Blepharospasm Disability Index (BSDI),17 the Patient 
Evaluation of Global Response,90 and the Global Assess-
ment Scale.91 Both agents significantly reduced mean 
BSDI scores and Patient Evaluation of Global Response 
scores from baseline to the control visit and the final 
visit (P , 0.0001 for all changes), with no significant 
differences between incobotulinumtoxinA and onabotu-
linumtoxinA observed. For the Global Assessment Scale 
measure, investigators rated the efficacy of the medication 
as “very good” in a slightly higher percentage of patients 
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Figure  4  Mean  change  from  baseline  in  Jankovic  Rating  Scale  total  score  at 
week three and at final visit (up to 16 weeks) after a single injection of either 
incobotulinumtoxinA or onabotulinumtoxinA in 300 patients with blepharospasm.
Note: *P , 0.0001 versus baseline (analysis of covariance).90
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in the incobotulinumtoxinA group (34.9%) than in the 
  onabotulinumtoxinA group (28.4%); however, this differ-
ence was not significant.89
Both study medications were well tolerated, with 
slightly fewer total AEs reported in the incobotulinum-
toxinA group (56 events) than in the onabotulinumtoxinA 
group (62 events). The most commonly occurring AE with 
both agents was eyelid ptosis, which was reported in 6.1% 
of incobotulinumtoxinA-treated patients versus 4.6% of 
onabotulinumtoxinA-treated individuals (Table 4).89
IncobotulinumtoxinA was also compared with onabotu-
linumtoxinA in a smaller randomized, double-blind, parallel-
group, pilot trial.92 Patients with BSP previously treated with 
onabotulinumtoxinA ($20 U per eye) and scores .2 on the 
JRS (n = 65) received 20–45 U per eye of incobotulinum-
toxinA (n = 33) or onabotulinumtoxinA (n = 31) during a 
single treatment session. Patients were evaluated at 4, 8, and 
14 weeks postinjection. The primary outcome variable was 
change in BSDI at week four. BSDI decreased from baseline 
in both groups at week four (1.3 for incobotulinumtoxinA 
and 2.8 for onabotulinumtoxinA) and at week eight (0.8 for 
incobotulinumtoxinA and 1.3 for onabotulinumtoxinA). 
JRS score decreased by 1.5 (both eyes) at week four and 
1.3 (both eyes) at week eight for incobotulinumtoxinA. 
JRS score decreased by 2.3 (OS) and 2.2 (OD) at week 
four and 1.9 (both eyes) at week eight with onabotulinum-
toxinA treatment. There were no significant differences 
between BoNT/A products in these outcome variables or 
any predefined outcomes. AE profiles were similar with 
periorbital hematoma reported most frequently (27% for 
incobotulinumtoxinA and 23% for onabotulinumtoxinA), 
followed by headache (21% for incobotulinumtoxinA and 
23% for onabotulinumtoxinA).92
The safety and efficacy of incobotulinumtoxinA versus 
placebo was further evaluated in a larger, randomized, 
double-blind study in patients with BSP with documented 
satisfactory response to two previous treatments with 
  onabotulinumtoxinA and JRS severity subscores $2.93 
A total of 109 patients were randomized in a 2:1 ratio to 
an individual dose of incobotulinumtoxinA, at up to 50 U 
per eye, or placebo, and were followed for up to 20 weeks. 
The primary efficacy measure was change from baseline 
at 6 weeks postinjection in the JRS severity subscore, as 
assessed by a blinded independent investigator. At 6 weeks, 
the JRS severity subscore had improved significantly 
more in the incobotulinumtoxinA group, by −0.83 points, 
compared with a 0.21 increase (worsening) with placebo, 
resulting in a difference of 1.0 favoring incobotulinum-
toxinA (P , 0.001).93 Functional impairment as indicated 
by BSDI scores improved by 0.5 points with incobotuli-
numtoxinA compared with placebo (P = 0.002). AEs were 
reported in 70.3% of patients in the incobotulinumtoxinA 
group and 58.8% in the placebo group. The most com-
monly reported AEs (incobotulinumtoxinA versus placebo) 
were eyelid ptosis (18.9% versus 5.9%), dry eye (18.9% 
versus 11.8%), and dry mouth (14.9% versus 2.9%). Toler-
ability was rated as good/very good by 91.9% patients in 
the   incobotulinumtoxinA group compared with 85.2% of 
placebo patients.
Pooled data analyses
Pooled analyses of data from multiple clinical trials were con-
ducted to evaluate the overall efficacy, safety, and tolerability 
of incobotulinumtoxinA across both CD and BSP patient 
  populations. In one such analysis, efficacy data were pooled 
from two pivotal clinical trials in patients with CD and BSP,51,89 
which included a total of 343   incobotulinumtoxinA-treated 
patients and 340 onabotulinumtoxinA-treated patients, as 
well as one trial for the treatment of spasticity in poststroke 
patients, which included 73 incobotulinumtoxinA-treated 
patients and 75 placebo-treated individuals.94 For the evalu-
ation of safety and tolerability, this analysis also pooled data 
from six clinical trials in patients with BSP, CD, and upper 
limb spasticity, including 539 incobotulinumtoxinA-treated 
patients, 442 onabotulinumtoxinA-treated patients, and 75 
placebo-treated patients. The results of this analysis showed 
Table 4 Adverse events following a single injection of either 
incobotulinumtoxinA  or  onabotulinumtoxinA  in  300  patients 
with blepharospasm90
Adverse event,  
n (%)
IncobotulinumtoxinA 
(n = 148)
OnabotulinumtoxinA 
(n = 152)
Ptosis 9 (6.1) 7 (4.6)
Abnormal vision 
Back pain 
Rash 
Upper respiratory  
tract infection 
Face edema 
Xerophthalmia 
Arthralgia 
Dizziness 
Headache 
Paresthesia 
Depression 
Palpitation 
Photophobia 
Dyspnea
2 (1.4) 
2 (1.4) 
1 (0.7) 
 
1 (0.7) 
1 (0.7) 
3 (2.0) 
1 (0.7) 
2 (1.4) 
1 (0.7) 
1 (0.7) 
0 (0.0) 
0 (0.0) 
2 (1.4) 
2 (1.4)
5 (3.3) 
4 (2.6) 
2 (1.3) 
 
2 (1.3) 
2 (1.3) 
0 (0.0) 
1 (0.7) 
0 (0.0) 
1 (0.7) 
1 (0.7) 
2 (1.3) 
2 (1.3) 
0 (0.0) 
0 (0.0)
Urinary tract  
infection
 
2 (1.4)
 
0 (0.0)
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that incobotulinumtoxinA and onabotulinumtoxinA have 
equivalent efficacy, with similar onset, waning, and duration 
of effect. These results were confirmed by similar ratings for 
both agents in the physician Global Impression of Efficacy, 
in which 70.6% of onabotulinumtoxinA-treated patients and 
71.8% of incobotulinumtoxinA-treated patients were rated 
as “good” or “very good.” No clinically relevant differences 
were detected between active treatment groups in the focal 
dystonia trials, or between incobotulinumtoxinA and placebo 
in the poststroke spasticity trials. All AEs were either already 
known and/or were judged by the investigator as unlikely to 
be related to incobotulinumtoxinA treatment. This analysis 
further estimated that as of 2009, .67,000 patients had 
been treated with incobotulinumtoxinA, with no new safety 
concerns having been reported.95
Another pooled analysis was conducted to   evaluate 
the efficacy of incobotulinumtoxinA in CD and BSP 
  populations.95 This analysis included two active-controlled 
trials51,89 and two placebo-controlled trials,84,93 one each in the 
CD and BSP populations. Efficacy data were available for a 
total of 613 patients who had received   incobotulinumtoxinA 
  treatment. In the placebo-controlled studies, the mean percent-
age improvement with incobotulinumtoxinA versus placebo 
in the primary efficacy outcomes was similar across studies 
(23.2%–26.5%), and patient-evaluated global response to 
treatment was significantly superior compared with placebo 
(P , 0.001); 53.4% of incobotulinumtoxinA-treated patients 
reported at least moderate symptomatic improvement com-
pared with 12.0% of placebo-treated individuals. Across the 
four studies, the mean onset of treatment was 6.0–7.7 days, 
the mean waning of effect was 6.5–10.6 weeks, and the mean 
duration of effect was 10.6–14.0 weeks.95
In addition, a review of the AEs in the two noninferiority 
trials of incobotulinumtoxinA and onabotulinumtoxinA showed 
that most AEs associated with the use of either agent were of 
mild or moderate severity (Table 5).80 The incidence of SAEs 
was also low across both studies, occurring at a slightly lower 
rate with incobotulinumtoxinA than with onabotulinumtoxinA; 
no deaths were reported during these trials (Table 5).80 None of 
the SAEs was considered to be related to the study medication in 
either trial; no AEs led to treatment withdrawal in the incobotu-
linumtoxinA groups, whereas only one withdrawal due to an AE 
was reported with the use of onabotulinumtoxinA (Table 5).80
Review of the data
Overall, a considerable amount of preclinical and clinical trial 
data on incobotulinumtoxinA has been collected, including 
individual studies and pooled analyses of these studies. The 
preclinical data established that incobotulinumtoxinA will 
remain stable for up to 4 years at room temperature79 and 
demonstrated a low risk for diffusion from target tissues 
following injection, which is similar to that with onabotuli-
numtoxinA.68 In addition, preclinical data demonstrated that 
incobotulinumtoxinA has a low potential for immunogenicity 
leading to treatment failure, which was lower than that with 
onabotulinumtoxinA.80 In an ongoing clinical trial in patients 
with CD, no cases of antibody formation were reported in 100 
patients who had been treated for .1 year and in 34 patients 
treated continuously for .2 years.94 In clinical studies in 
healthy volunteers, incobotulinumtoxinA also demonstrated a 
similar pharmacologic profile to   onabotulinumtoxinA in terms 
of onset of effect, duration of effect, and overall efficacy,51,81 
as well as pharmacodynamic actions and adverse effects.80
Randomized, active-controlled, clinical studies have 
shown that incobotulinumtoxinA is noninferior in efficacy to 
onabotulinumtoxinA for the treatment of both CD and BSP.51,89 
A randomized, controlled study also determined that incobotu-
linumtoxinA significantly reduced CD symptoms compared 
with placebo in BoNT-naïve and nonnaïve patients.84,86,87 
In patients with BSP who had been previously treated with 
BoNT, incobotulinumtoxinA significantly reduced BSP 
symptoms compared with placebo.93 Across the clinical CD 
trials, both the primary efficacy measures (which were either 
the TWSTRS total score or the TWSTRS severity score in all 
trials) and the secondary outcomes (including both patient- 
and physician-rated scales) demonstrated the noninferiority of 
incobotulinumtoxinA to onabotulinumtoxinA and significant 
benefits, compared with placebo. In patients with BSP previ-
ously treated with BoNT, secondary measures, including the 
BSDI, Patient Evaluation of Global Response, and Global 
Assessment Scale, also supported the primary outcome result 
(JRS total score) in demonstrating the noninferiority of inco-
botulinumtoxinA to   onabotulinumtoxinA and the superiority 
of incobotulinumtoxinA compared with placebo.17,89,93
With regard to safety and tolerability, incobotulinum-
toxinA is well tolerated, and has demonstrated an AE profile 
similar to that of onabotulinumtoxinA in both CD and BSP 
patients (Tables 3 and 4).51,89 Most AEs associated with 
either agent are of mild to moderate severity, and few have 
led to withdrawal from treatment (Table 5).80 It also should 
be noted that incobotulinumtoxinA is contraindicated in 
people with known hypersensitivity to BoNT/A or to any 
of the excipients used in this product (Table 1), or with 
generalized disorders of muscle activity (eg, myasthenia 
gravis, Lambert–Eaton syndrome).73,80 Patients treated with 
incobotulinumtoxinA should be closely observed when 
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there is concomitant use of agents that may potentiate the 
effects of incobotulinumtoxinA, including aminoglycoside 
antibiotics, spectinomycin, or other agents that interfere with 
neuromuscular transmission (eg, tubocurarine-like agents), 
or muscle relaxants.73,80
Conclusion
IncobotulinumtoxinA is a safe and effective agent, compared 
with placebo, for the treatment of patients with CD or BSP 
and is noninferior to onabotulinumtoxinA. Based on the 
results of clinical trials, incobotulinumtoxinA is indicated 
in the United States for the treatment of adults with CD and 
for the treatment of BSP in adults previously treated with 
onabotulinumtoxinA. The absence of complexing proteins 
in this formulation of BoNT/A does not seem to confer any 
differences in preinjection stability, risk for diffusion outside 
of target muscles, or time course of response following injec-
tion. By contrast, the risk for immunogenicity and possible 
treatment failure may be lower than that with other formula-
tions. However, additional long-term clinical data regarding 
immunogenicity are warranted.
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